Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and BeyondAlistair Mathie, Paul D. Wright, Robyn G. Holden et al.|The Annual Review of Pharmacology and Toxicology|2020Cited by 73
Characterization and regulation of wild‐type and mutant TASK‐1 two pore domain potassium channels indicated in pulmonary arterial hypertensionKevin P. Cunningham, Alistair Mathie, Robyn G. Holden et al.|The Journal of Physiology|2018Cited by 53
Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channelsKevin P. Cunningham, Emma L. Veale, D. Euan MacIntyre et al.|Acta Physiologica|2019Cited by 25
The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium ChannelsKevin P. Cunningham, Emma L. Veale, Lucie H. Clapp et al.|Frontiers in Pharmacology|2021Cited by 7
The Role of the K2P Channels TASK‐1, TREK‐1 and TREK‐2 in the Use of Treprostinil Therapy in Pulmonary Arterial HypertensionKevin P. Cunningham, Alistair Mathie, Jeries Abu‐Hanna et al.|The FASEB Journal|2018Cited by 4